Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 269

Related Articles by Review for PubMed (Select 11410481)

1.

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R.

Clin Cancer Res. 2001 Jun;7(6):1490-6. Erratum in: Clin Cancer Res 2002 Jan;8(1):300.

2.

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.

Stasi R.

Expert Opin Biol Ther. 2008 Apr;8(4):527-40. doi: 10.1517/14712598.8.4.527 . Review.

PMID:
18352855
3.

Current use and future development of gemtuzumab ozogamicin.

Larson RA.

Semin Hematol. 2001 Jul;38(3 Suppl 6):24-31. Review.

PMID:
11474494
4.
5.

Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg).

Sievers EL.

Blood Cells Mol Dis. 2003 Jul-Aug;31(1):7-10. Review.

PMID:
12850477
6.

Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.

Giles FJ.

Expert Rev Anticancer Ther. 2002 Dec;2(6):630-40. Review.

PMID:
12503209
7.

Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia.

Fenton C, Perry CM.

Drugs. 2005;65(16):2405-27. Review.

PMID:
16266206
8.
9.

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.

Stadtmauer EA.

Curr Oncol Rep. 2002 Sep;4(5):375-80. Review.

PMID:
12162910
10.

Gemtuzumab ozogamicin.

McGavin JK, Spencer CM.

Drugs. 2001;61(9):1317-22; discussion 1323-4. Review.

PMID:
11511025
11.

The role of gemtuzumab ozogamicin in acute leukaemia therapy.

Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM.

Br J Haematol. 2006 Feb;132(4):398-409. Review.

PMID:
16412015
12.

Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse.

Berger MS, Leopold LH, Dowell JA, Korth-Bradley JM, Sherman ML.

Invest New Drugs. 2002 Nov;20(4):395-406. Review.

PMID:
12448657
13.

Technology evaluation: gemtuzumab ozogamicin, Celltech Group.

Niculescu-Duvaz I.

Curr Opin Mol Ther. 2000 Dec;2(6):691-6. Review.

PMID:
11249747
14.

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.

Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S.

Cancer Treat Rev. 2008 Feb;34(1):49-60. Epub 2007 Oct 17. Review.

PMID:
17942233
15.

[Therapeutic advances in neoplastic hematology: target therapy anti-CD33].

Di Rocco A, Finolezzi E, Anaclerico B, Calabrese E, Levi A, Trasarti S, Tafuri A.

Clin Ter. 2005 Jul-Aug;156(4):183-6. Review. Italian.

PMID:
16342520
16.

Mylotarg: antibody-targeted chemotherapy comes of age.

Sievers EL, Linenberger M.

Curr Opin Oncol. 2001 Nov;13(6):522-7. Review.

PMID:
11673694
17.

Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.

Leopold LH, Berger MS, Feingold J.

Clin Lymphoma. 2002 Mar;2 Suppl 1:S29-34. Review.

PMID:
11970768
18.

Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia.

Voutsadakis IA.

Anticancer Drugs. 2002 Aug;13(7):685-92. Review.

PMID:
12187324
19.

Monoclonal antibodies for the treatment of acute myeloid leukemia.

Abutalib SA, Tallman MS.

Curr Pharm Biotechnol. 2006 Oct;7(5):343-69. Review.

PMID:
17076651
20.

What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?

Molnár I, Powell BL.

Curr Hematol Malig Rep. 2007 May;2(2):104-10. doi: 10.1007/s11899-007-0015-1. Review.

PMID:
20425358
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk